CancerAppy is a biotech specialized in the field of cancer research, focused on the discovery and development of new therapeutic targets, based on its own artificial intelligence methodology
Cancer: a global problem
Cancer is a global problem and the identification of novel therapies is an urgent need. Unfortunately, drug development is a long lasting and expensive process with a high risk of failure.
Incorporation of targeted therapies challenge physicians and healthcare providers to adapt their systems to provide an easy and sustainable access to personalize medicine.
Better medicines for a personalized care
CancerAppy aims to resolve this problem by de-escalating the risk of drug development helping healthcare providers to optimize and improve their services.
By using big data, machine learning and biology at a global scale, CancerAppy seeks to enable better medicines for a personalized care.
We do work at four different scales in an integrated manner by using global biology data, therapeutic structural efficacy information, machine learning and real world patient data.
Our style: Where science meets artificial intelligence
Our team at CancerAppy is highly diversified, with practical experience, profound knowledge and subject matter expertise in oncology research, patient care and computer science. This enables us to provide cutting edge solutions, using science and artificial intelligence, at a global scale to hospitals, academic institutions, pharmaceutical companies and a wide range of players involved in patient care and cancer research.
Transforming the world of cancer research
With our platform we fill the gap between basic data and pharma intelligence tools. Our mission is to empower scientists, researchers, physicians and healthcare providers with the global benchmark in cancer research and patient treatment. This will let us transform the world of cancer research and eventually improve the lives of millions of people, globally.
Target Identification
We combine our expertise in biology and AI to identify new therapeutic targets.
Lead Identification
We combine our expertise in chemistry and AI to identify new therapeutic targets.
Mechanism of action
We find the possible mechanism of action of a selected compound.
Thanks to our deep knowledge and expertise in oncology and AI, we use a massive amount of multimodal data in our state-of-the-art AI algorithms, helping to identify new therapeutic targets, identify lead compounds, and determine the mechanism of action of a given compound. as well as possible drug combinations.
Contact us
We would be happy to talk to you.
Our AI Platform comprises of DrugOptimization to identify and validate novel targets and/or identify the mechanism of action of a compound, DrugCombination to explore potential drug combinations providing a score for the mixed drugs, and GeneReport which is a personalized treatment matched application that permits score predicted treatments with patient genomic actionable information.
News
Latest news about CancerAppy…
HONG KONG INVEST – European Companies Roadshow
From 15th to 18th of May, our CEO and CMO will be attending various international events in Hong Kong introducing the latest advances of our company. They will attend Asia Summit on Global Health, Invest in Honk Kong #investHK, and different meeting with local...
MEET2WIN_23
Our CEO Luis Martín Ezama will be attending the #Meet2win23 event 11th and 12th of May, exposing the characteristics of our pipeline of new cancer drugs. We are developing first-in-class antibodies and small molecules against solid tumors.
Anglonordic 23 – London
April 20th. We are going to attend the 19th Annual Anglonordic Life Science Conference.Meet us to discuss face to face about our latest works: CA04 first-in-class monoclonal antibody, CA05 first-in-class kinase inhibitor and CA07 novel PROTAC.We can’t wait to hear...
Grant CPP2021-008597 funded by:
Grant TQ2020-011486 funded by:
Subvencionado por el CDTI
Somos cliente Enisa
Find us at:
